Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (June 2023)

53 slides from Day One Biopharmaceuticals's investor presentation, Jun 12, 2023

  1. Slide 1: Targeted Therapies for People of All Ages

    Exhibit 99.1 Day One Biopharmaceuticals Targeted Therapies for People of All Ages June 2023 Day One Biopharmaceuticals

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Drug Development For People Of All Ages

    Cancer Drug Development For People Of All Ages Tovorafenib (DAY101) Mission That Growing Portfolio and Runway Creates Value Lead Program Beyond Clinical Milestones • Day One’s mission is to help children • Investigational, oral, CNS-penetrant • Two clinical-stage MEKi assets, in- with cancer, from d

  4. Slide 4: Our Pipeline

    Our Pipeline Recent & Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Initiated rolling NDA submission: May 2023 Tovorafenib (DAY101) New clinical data presented: 1 Relapsed pLGG Type II Pan-RAF Inhibitor FIREFLY-1 (pivotal) June 2023 Expected rolling NDA subm

  5. Slide 5: Tovorafenib (DAY101) Type II RAF Inhibitor

    Tovorafenib (DAY101) Type II RAF Inhibitor Day One Biopharmaceuticals

  6. Slide 6: Pediatric Low-Grade Gliomas (pLGG)

    Pediatric Low-Grade Gliomas (pLGG) • Despite being the most common brain tumor in children, there are no approved agents and no standard-of-care for the majority of patients with 1,2 relapsed/progressive disease ‒ ~70% of patients will require systemic therapy ‒ Patients have a high rate of recurren

  7. Slide 7: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions And BRAF V600 Mutations • Tovorafenib (DAY101) is an investigational, MAPK pathway RAS-independent activation of the MAPK pathway oral, selective, CNS-penetrant, type II pan- RAF inhibitor that was designed to inhibit RAS both monomeric and dimeric RAF

  8. Slide 8: The Current pLGG Treatment Paradigm

    The Current pLGG Treatment Paradigm Reflects The Unrelenting Nature Of This Chronic Brain Tumor 1L 2L 3L Presentation Surgical Intervention ~35% ~20% Targeted Tx Targeted Tx Targeted Tx GTR No Recurrence (5-10%) (40-50%) (40-50%) 1 Biopsy (>95%) Suspected ~65% ~50% ~50% pLGG ≤ Partial Eventual Addit

  9. Slide 9: Progress Of FIREFLY-1 Program

    Progress Of FIREFLY-1 Program: Monotherapy Tovorafenib In Relapsed pLGG Updated Clinical Data from FIREFLY-1 Trial Presented at ASCO Pre-NDA Meeting (Jun 2023) Interim Analysis Data (Apr 2023) from FIREFLY-1 Trial (Jun 2022) First Patient Dosed in FIREFLY-1 Trial (May 2021) Initiated Rolling NDA Exp

  10. Slide 10: Pivotal Phase Trial Of Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) In Relapsed Or Progressive pLGG (FIREFLY-1) Trial Design Endpoints (Pivotal Arm 1) 1 • Three arm, open-label, global registrational phase 2 trial • Primary endpoint: ORR based on RANO-HGG , assessed by blinded independent central review • Piv

  11. Slide 11: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics Location (n=77) Deep midline structures Characteristic Arm 1 (n=77) 12% Optic pathway 51% Median age, years (range) 8 (2-21) Other Sex, n (%) * 16% Male 40 (52) Cerebral hemisphere Female 37 (48) 8% Cerebellum Race, n (%) 6% Brain stem Black or African Amer

  12. Slide 12: Tumor Response By RANO-HGG (n=69)

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-HGG Evaluable Lesions (n=69) 1 RANO-HGG Response (IRC) Evaluable n=69 ORR (cCR + cPR + uPR), n (%) 46 (67%)* Clinical benefit rate, n (%) cCR, cPR/uPR, or SD 64 (93%) cCR, cPR/uPR, or SD for 12 mo+ 49 (71%) Best overall response, n (%

  13. Slide 13: Tumor Response By RAPNO-LGG (n=69)

    Tumor Response To Tovorafenib (DAY101) For All Patients With RAPNO-LGG Evaluable Lesions (n=69*) 1 RAPNO-LGG Response (IRC) Evaluable n=69 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 35 (51%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD 60 (87%) cCR, cPR/uPR, cMR/uMR, or SD for 12mo+ 36 (52%)

  14. Slide 14: Tumor Response By RANO-LGG (n=76)

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-LGG Evaluable Lesions (n=76) 1 RANO-LGG Response (IRC) Evaluable n=76 ORR (cCR + cPR/uPR + cMR/uMR), n (%) 37 (49%) Clinical benefit rate, n (%) cCR, cPR/uPR, cMR/uMR, or SD 63 (83%) cCR, cPR/uPR, cMR/uMR, or SD for 12mo+ 39 (51%) Bes

  15. Slide 15: Duration Of Therapy For RANO-HGG Evaluable Patients

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions (n=69) 2.8 Median time to response* MONTHS 11/17 patients with stable disease <12 months remain on treatment as of data cutoff Median duration of 10.8 MONTHS treatment* Ongoing treatment Partial response Discon

  16. Slide 16: Duration Of Therapy RANO-HGG & RANO-LGG

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG & RANO-LGG Evaluable Lesions RANO-HGG (n=69) RANO-LGG (n=76) As of the data cutoff, As of the data cutoff, the median IRC- the median IRC- assessed DOR based on assessed DOR based on RANO-HGG criteria was RANO-LGG criteria was n

  17. Slide 17: Unconfirmed PR Patients Continue On Treatment With Deepening Response

    All RANO-LGG Unconfirmed PR Patients Continue On Treatment With Demonstrable Deepening Of Response (n=8) Responses for Patients with Unconfirmed Partial Response by RANO-LGG SD MR PR CR Months from Baseline All 8 patients with unconfirmed partial response by RANO-LGG remain on treatment as of May 23

  18. Slide 18: Best Response Of PD By RANO-LGG Patients With Stabilization

    Nearly Half Of Patients With Best Response Of PD By RANO-LGG Have Tumor Stabilization And Response With Continued Treatment (n=11) Ongoing treatment Discontinued treatment 5/11 patients with best response of PD by RANO-LGG remain on treatment as of May 23, 2023 Individual patient response data is cu

  19. Slide 19: Tovorafenib Safety Data (n=136)

    Tovorafenib (DAY101) Safety Data (n=136) • The vast majority of treatment-emergent AEs Treatment-emergent AEs Treatment-related AEs were Grade 1 or 2 Preferred term, n (%) Any grade Grade ≥3 Any grade Grade ≥3 • 39 patients (29%) required dose modifications Any AE 136 (100) 68 (50) 133 (98) 47 (35)

  20. Slide 20: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma 8-year-old boy with relapsed pilomyxoid astrocytoma of the optic pathway, with visual loss in right eye, visual field loss in left eye, fatigue, intermittent nausea/vomiting, intermittent headaches, anorexia, a

  21. Slide 21: Key Takeaways And Next Steps

    Key Takeaways And Next Steps • Clinically meaningful data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusions or BRAF V600E mutations, for whom there is no standard-of-care and no approved agents for the majority of patients • 67% ORR and 93% clinical benef

  22. Slide 22: Incidence And Prevalence Of BRAF-Altered pLGG In The U.S.

    Incidence And Prevalence Of BRAF-Altered pLGG In The U.S. 2020 2017 Estimated Incidence Estimated SEER Prevalence Under 25 Under 25 1 US Population ~105,000,000 NA 2 3 Rate of CNS Tumors (0.00521%) ~5,500 ~130,000 2 Gliomas (63%) ~3,500 ~82,000 2 Low Grade (77%) ~2,600 ~63,000 2 Has Received Drug Tx

  23. Slide 23: FIREFLY-2/LOGGIC Pivotal Phase Trial in Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG Day One Biopharmaceuticals Confidential Information

  24. Slide 24: FIREFLY-2/LOGGIC Trial Design And Endpoints

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib (DAY101) In Newly Diagnosed pLGG Trial Design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RANO-LGG criteria, assessed by blinded 1 (DAY101) vs SoC chemotherapy independe

  25. Slide 25: FIREFLY-2/LOGGIC: Collaboration And Sites

    FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG • Collaboration between Day One and the Approximately 100 potential sites (~65 from the LOGGIC consortium) LOGGIC consortium, internationally recognized experts in pLGG research ‒ Coupled with the LOGGIC-CORE mol

  26. Slide 26: Our Pipeline

    Our Pipeline Recent & Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones Initiated rolling NDA submission: May 2023 Tovorafenib (DAY101) New clinical data presented: 1 Relapsed pLGG Type II Pan-RAF Inhibitor FIREFLY-1 (pivotal) June 2023 Expected rolling NDA subm

  27. Slide 27: Monotherapy Tovorafenib In Solid Tumors (FIRELIGHT-1)

    Phase 2 Study Of Monotherapy Tovorafenib (DAY101) In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints • Single arm, open-label, global phase 1b/2a trial • Primary endpoint: ORR by RECIST version 1.1 for non-CNS solid tumors and RANO-HGG criteria for any CNS tumors • n = 40 patients (approximately

  28. Slide 28: Clinical Activity In BRAF Fusion Melanoma: Patient 1

    Preliminary Clinical Activity Of Tovorafenib (DAY101) Monotherapy In BRAF Fusion Melanoma Patient 1: 53-year-old male with AGK-BRAF fusion non-spitzoid cutaneous melanoma Parameter Description/outcome Stage at diagnosis III EGOC status 0 • Multiple lymphadenectomies and skin lesion excision surgery

  29. Slide 29: Clinical Activity In BRAF Fusion Melanoma: Patient 2

    Preliminary Clinical Activity Of Tovorafenib (DAY101) Monotherapy In BRAF Fusion Melanoma Patient 2: 35-year-old male with TRIM33-BRAF fusion malignant melanoma Parameter Description/outcome Stage at diagnosis Unknown EGOC status 1 • Radiation • Nivolumab (12 mo, adjuvant setting): Prior therapies ‒

  30. Slide 30: Clinical Activity In BRAF Fusion Melanoma: Patient 3

    Preliminary Clinical Activity Of Tovorafenib (DAY101) Monotherapy In BRAF Fusion Melanoma Patient 3: 71-year-old male with MKRN1-BRAF fusion non-spitzoid cutaneous melanoma Parameter Description/outcome Stage at diagnosis II EGOC status 0 • Radiation Prior therapies • Pembrolizumab (2 mo): ‒ Best re

  31. Slide 31: Activity In SNX8:BRAF Fusion Spindle Cell Sarcoma

    Activity of Tovorafenib (DAY101) In SNX8:BRAF Fusion Spindle Cell Sarcoma A male child spindle cell sarcoma, 5-years of age at diagnosis Months -30 -24 -18 -12 -6 0 6 CR PD CR Diagnosis Targeted Therapy BRAF fusion (FISH) Ifosfamide, doxorubicin, Tovorafenib Tovorafenib Subtotal resection dexrazoxan

  32. Slide 32: Scientific Rationale For Combining Tovorafenib With MAPK Pathway Inhibitors

    Strong Scientific Rationale for Combining Tovorafenib (DAY101) With Additional MAPK Pathway Inhibitors BRAF BRAF or CRAF KRAS or NRAS NF1 non-V600 fusion mutant LOF MEK MEK RAF/ PI3K/m RAS/RAF/ PI3K/ Signaling RAL MEK/ERK TOR MEK/ERK mTOR pathways ERK ERK Proliferation, survival Proliferation, survi

  33. Slide 33: Pimasertib MEK1/2 Inhibitor

    Pimasertib MEK1/2 Inhibitor Day One Biopharmaceuticals

  34. Slide 34: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor With Demonstrated Activity In MAPK-Driven Solid Tumors • Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in- licensed from Merck KGaA in February 2021 • Extensive non-clinical and clinical devel

  35. Slide 35: Vertical MAPK Pathway Inhibition With Tovorafenib And Pimasertib

    Vertical MAPK Pathway Inhibition With Tovorafenib (DAY101) And Pimasertib May Unlock Potential Synergy For Adult Solid Tumors BRAF KRAS or NRAS non-V600 mutant mutant MEK RAF/ PI3K/m RAL MEK/ERK TOR ERK Proliferation, survival Proliferation, survival Type II RAFi + MEKI Type II RAFi + MEKi Pan-RAFi

  36. Slide 36: Tovorafenib / Pimasertib Combination In Solid Tumors (FIRELIGHT-1)

    Tovorafenib (DAY101) / Pimasertib Combination To Be Evaluated In Solid Tumors (FIRELIGHT-1) 1 Trial Design Endpoints 2 • Combination dose escalation, global phase 1b/2 trial • Phase 1b: PK, PD and Safety, MTD/RP2D • Phase 1b, BOIN (adaptive), n = 10/cohort (approximately) • Phase 2: Efficacy (ORR, D

  37. Slide 37: Summary

    Summary Day One Biopharmaceuticals

  38. Slide 38: Financial Summary

    Financial Summary: DAWN Follow-on in June 2023: $172.5 million in gross Cash, cash equivalents and short-term investments as 73.6 million shares of common stock of March 31, 2023: $318.2 million (no debt) proceeds, includes full exercise of underwriters’ option outstanding as of April 25, 2023 Three

  39. Slide 39: Next Steps

    Next Steps FIREFLY-1 • Initiated rolling NDA submission in May 2023 • New clinical data presented in June 2023 • Expected completion of rolling NDA submission in October 2023 FIREFLY-2 • Advance tovorafenib as a front-line therapy for patients newly diagnosed with pLGG FIRELIGHT-1 • Evaluate tovoraf

  40. Slide 40: Appendix

    Appendix ` 40

  41. Slide 41: FIREFLY-1 Baseline Characteristics

    FIREFLY-1 Baseline Characteristics Characteristic Arm 1 (N=25) Location (n=25) Median age, years (range) 8 (3-18) Deep midline structures Hypothalamus 12% Sex, n (%) 8% Male 13 (52) Other Female 12 (48) 16% Optic pathway Race, n (%) 52% Black or African American 1 (4) Cerebellum Brain stem Asian 2 (

  42. Slide 42: Tumor Response By RANO-HGG (n=22)

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-HGG Evaluable Lesions (n=22)* RANO-HGG Response (IRC) Evaluable N=22* ORR (95% CI) 64% (41-83) • BRAF fusion (n=20) 60% • BRAF V600E (n=2) 100% # CBR 91% Best overall response • PR (13/22) 59% • uPR (1/22) 5% • SD (6/22) 27% Apr 14, 2

  43. Slide 43: Duration Of Therapy For RANO-HGG Evaluable Patients (n=22)

    Duration Of Tovorafenib (DAY101) Therapy For All Patients With RANO-HGG Evaluable Lesions (n=22) 17/22 patients remain on therapy All responders remain on treatment Apr 14, 2022 data cutoff. Day One Biopharmaceuticals 43

  44. Slide 44: Individual Patient Tumor Change From Baseline

    Individual Patient Tumor Change From Baseline (n=22 RANO-HGG Evaluable By Blinded Independent Central Review) PD SD PR CR Months Apr 14, 2022 data cutoff. RANO PD = ≥+25% change from baseline; RANO SD = <+24% to > -50% change from baseline; RANO PR = ≤ -50% Day One Biopharmaceuticals 44 change from

  45. Slide 45: Safety Data For The First Enrolled Patients

    Tovorafenib (DAY101) Safety Data For The First 25 Enrolled Patients (TEAEs ≥25% Any Grade) Treatment-emergent AEs Treatment-related AEs Any grade Grade ≥3 Any grade Grade ≥3 Preferred term, n (%) Blood creatine phosphokinase increased 20 (80) 2 (8) 18 (72) 2 (8) • Most treatment-emergent AEs were gr

  46. Slide 46: Key Takeaways

    Key Takeaways • Encouraging initial efficacy data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusion or BRAF V600 mutation, for whom there is no standard-of-care and no approved agents for the majority of patients ‒ 64% ORR and 91% clinical benefit rate (pa

  47. Slide 47: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549- BRAF Fusion Optic Pathway Glioma A 7-years-old female child with an optic pathway glioma, with very poor vision, entropion, folliculitis, eczema, mouth ulceration and xerosis -36 6 Months -30 -24 -18 -12 -6 0 PR Diagnostic biopsy 3L: Tovorafe

  48. Slide 48: Case Study: KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma An 8-years-old female child with a posterior fossa pilocytic astrocytoma, eczema, nausea and constipation Months -84 -72 -60 -48 -36 -24 -12 0 12 PR Suboccipital 2L: Carboplatin/vincristine cra

  49. Slide 49: Case Study: BRAF V600E Mutation Deep Midline Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma A 9-year-old female child with deep midline BRAF V600E-mutant astrocytoma with precocious puberty Months -60 -48 -36 -24 -12 0 12 PR Subtotal 1L: Carboplatin/vincristine 2L: Dabrafenib 3L: Tovorafenib resect

  50. Slide 50: Results From Independent Radiology Review Of PNOC014

    Results From Independent Radiology Review Of PNOC014 Best response from baseline RANO-HGG: Response assessment for neuro- oncology-high grade glioma Volumetric image analysis (exploratory) RAPNO: Response assessment for pediatric neuro-oncology (exploratory) Date of data cutoff: 02 JAN 2020 Wright K

  51. Slide 51: Rapid, Deep And Durable Responses In PNOC014

    Multiple Rapid, Deep And Durable Responses Observed Following Initiation Of Tovorafenib (DAY101) Treatment Of pLGG Patients In PNOC014 Growth kinetics of Target Lesions from Screening Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et

  52. Slide 52: Drug-related Adverse Events In PNOC014

    Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Drug-related AEs for Tovorafenib (DAY101) Drug-related AEs for selumetinib Toxicities Grade 1-2 Grade 3 Grade 4 Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Increa

  53. Slide 53: Patients With RANO-LGG Confirmed Minor Response Remain On Treatment

    The Majority Of Patients With RANO-LGG Confirmed Minor Response Remain On Treatment (n=15) Ongoing treatment Discontinued treatment 12/15 patients with confirmed minor response by RANO-LGG remain on treatment as of May 23, 2023 Individual patient response data is current as of the data cutoff of Dec

Day One Biopharmaceuticals — Investor Presentation (June 2023) on 6ix